Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Antibody, R&D Systems™

ErbB2/Her2

Flow Cytometry 0.25 ug/10^6 cells, Inhibition of Cell Growth 15-75 ng/mL, CyTOF-ready

Monoclonal

Supernatant

Human

CD340, CD340 antigen, c-erb B2/neu protein, EC 2.7.10, EGFR2, HER2, HER-2, HER2EC 2.7.10.1, herstatin, Metastatic lymph node gene 19 protein, MLN 19, MLN19, Neu Oncogene, NEUHER-2/neu, neuroblastoma/glioblastoma derived oncogene homolog, NGL, NGLTKR1, p185erbB2, Proto-oncogene c-ErbB-2, Proto-oncogene Neu, receptor tyrosine-protein kinase erbB-2, TKR1, Tyrosine kinase-type cell surface receptor HER2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2(neuro/glioblastoma derived oncogene homolog), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastomaderived oncogene homolog (avian)

Human ErbB2/Her2

Primary

Reconstitute at 0.5 mg/mL in sterile PBS.

Detects human ErbB2/Her2 in direct ELISAs. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Trastuzumab. This product is for research use only.

Hu5

Flow Cytometry, Inhibition Assays, CyTOF

Unconjugated

Human

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS.

2064

IgG1

Protein A or G purified from cell culture supernatant

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.